Case Report
Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines
| | Patient 1 | Patient 2 | Patient 3 |
| Sex/age (y)/race/smoke | F/59/Afro-American/— | M/60/African/— | F/71/Caucasian/— |
| Symptoms | Fever, cough, dyspnea, diffuse lung infiltrates, proximal muscle weakness | Fever, cough, dyspnea, basilar lung infiltrates, proximal muscle weakness | Proximal muscle weakness, severe dysphagia, periungueal erythema, periocular bullous heliotropic lesions | Onset after vaccination | 5 days | 30 days | 7 days |
| CK (nv < 170 U/L) 1-2-3 | 2,685-569-98 | 6,589-1,700-752 | 1,325-67-20 |
| EMG myogenic alterations | + | + | + |
| Autoimmunity | ANA 1 : 640 (speckled); ENA- ASMA-; AMA-; ANCA- | ANA 1 : 320 (speckled); ENA+ (Jo1); ASMA+ 1 : 160; AMA-; ANCA- | ANA 1 : 320 (speckled); ENA+ (Ro/SSA); AMA-; ASMA-; ANCA- |
| Treatment | 6-MP 1 mg/Kg/day → slowly tapered to 8 mg/day; Mycophenolate mofetil 2 g/day from February 2010 | Predn. 1.5 mg/Kg/day → slowly tapered to 25 mg/day Methotrexate 20 mg/week; IVIG 1 mg/kg monthly (February–May 2010); start of Cyclosporine 200 mg/day from September 2010 | 6-MP 1 mg/Kg/day → slowly tapered to 16 mg/day; IVIG 1 mg/kg monthly (March–August 2010) |
| Outcome | Remission | Partially improved | Died in November 2010 (Epstein-Barr virus reactivation) |
|
|
CK: creatinine kinase (1: at baseline; 2: 1 month after therapy beginning; 3: at the end of followup, in December 2010); EMG: electromyography; ANA: antinuclear antibodies; anti-ENA: antiextractable nuclear antigen antibodies; ASMA: antismooth muscle antibodies; AMA: antimitochondrial antibodies; ANCA: antineutrophil cytoplasmic antibodies; 6-MP: 6-methylprednisolone, Predn: prednisone.
|